SEC Form 4 · accession 0001209191-19-007882
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Cory
Officer — President and CEO · Director
Period of report
Feb 4, 2019
Accepted (ET)
Feb 6, 2019 · 7:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 4, 2019 | P | 227 | $14.13 | A | 58,678 | D | |
| Common StockF1 | holding | — | — | — | 30,123 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the Reporting Person's proportionate interest in securities held by Eiccose, LLC ("Eiccose"). The Reporting Person is a managing member and significant equity interest holder of Eiccose. The Reporting Person hereby disclaims any beneficial ownership of any shares directly held by Eiccose, except to the extent of its pecuniary interest therein.